Skip to content
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Heart icon (animated) heart icon (static)
Our Stories
Our Company
Follow Us
Explore more Johnson & Johnson sites:
Australia
A graphic of the flag of Australia alt
Argentina
A graphic of the flag of Argentina alt
Brazil
A graphic of the flag of Brazil alt
Canada
A graphic of the national flag of Canada alt
Chile
A graphic of the flag of Chile alt
China
A graphic of the national flag of the People's Republic of China alt
Colombia
A graphic of the national flag of Colombia alt
Costa Rica
A graphic of the national flag of Costa Rica alt
Czech Republic
Ecuador
A graphic of the national flag of Ecuador alt
Germany
A graphic of the flag of Germany alt
India
A graphic of the national flag of India alt
Japan
A graphic of the national flag of Japan alt
Mexico
A graphic of the flag of Mexico alt
New Zealand / Pacific
A graphic of the flag of New Zealand alt
Paraguay
A graphic of the flag of Paraguay alt
Peru
A graphic of the flag of Peru alt
Philippines
A graphic of the national flag of the Philippines alt
Russia
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
German
English
French
United Kingdom
A graphic of the national flag of the U.K. alt
United States
A graphic of the flag of the United States of America alt
Uruguay
A graphic of the national flag of Uruguay alt
Venezuela
A graphic of the flag of Venezuela alt
Share

Investor Information

Our Company
Save the Date: 2021 Business Review
Our business review focused on the Pharmaceuticals Sector will be held on November 18, 2021. Please save the date, and check back here for more details to follow.

Latest News Releases

Our Company
July 01, 2021
Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
Innovation
June 12, 2021
New Phase 3 Study Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Innovation
June 12, 2021
Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
See All News Releases
Webcast: 2020 Medical Devices Update
Webcast: 2020 Medical Devices Update
ON NOW Webcast: 2020 Medical Devices Update
2020 Health for Humanity Report
2020 Health for Humanity Report
ON NOW 2020 Health for Humanity Report
2020 Janssen U.S. Transparency Report
2020 Janssen U.S. Transparency Report
ON NOW 2020 Janssen U.S. Transparency Report
2020 Annual Report
2020 Annual Report
ON NOW A sign at Johnson & Johnson World Headquarters in New Brunswick, NJ alt 2020 Annual Report

Investor Relations

Investor FAQs
Answers to common questions regarding purchasing and owning Johnson & Johnson stock.
Learn More
ESG Resources
Effective management of ESG matters is a business imperative.
Learn More
Contact Investor Relations
Questions? Please contact Investor Relations:
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue